Rare urologic tumors

McCormick, Barrett Z.; Dahmen, Aaron; Antar, Ali; Baumgarten, Adam S.; Dhillon, Jasreman; Spiess, Philippe E.

doi:10.1097/mou.0000000000000356

Cited by 5 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, our results provided important observations about urethral cancer incidence and its trends over time. First, urethral cancer ASR is very low, relative to other urologic primaries [19][20][21][22]. Its ASR is highest in males, elderly patients, African Americans and in urothelial histological subtype.…”

Section: Discussionmentioning

confidence: 99%

Incidence rates and contemporary trends in primary urethral cancer

Wenzel

Nocera

Ruvolo

et al. 2021

Cancer Causes Control

View full text Add to dashboard Cite

Purpose We assessed contemporary incidence rates and trends of primary urethral cancer. Methods We identified urethral cancer patients within Surveillance, Epidemiology and End Results registry (SEER, 2004–2016). Age-standardized incidence rates per 1,000,000 (ASR) were calculated. Log linear regression analyses were used to compute average annual percent change (AAPC). Results From 2004 to 2016, 1907 patients with urethral cancer were diagnosed (ASR 1.69; AAPC: -0.98%, p = 0.3). ASR rates were higher in males than in females (2.70 vs. 0.55), respectively and did not change over the time (both p = 0.3). Highest incidence rates were recorded in respectively ≥75 (0.77), 55–74 (0.71) and ≤54 (0.19) years of age categories, in that order. African Americans exhibited highest incidence rate (3.33) followed by Caucasians (1.72), other race groups (1.57) and Hispanics (1.57), in that order. A significant decrease occurred over time in Hispanics, but not in other race groups. In African Americans, male and female sex-stratified incidence rates were higher than in any other race group. Urothelial histological subtype exhibited highest incidence rate (0.92), followed by squamous cell carcinoma (0.41), adenocarcinoma (0.29) and other histologies (0.20). In stage stratified analyses, T1N0M0 stage exhibited highest incidence rate. However, it decreased over time (−3.00%, p = 0.02) in favor of T1-4N1-2M0 stage (+ 2.11%, p = 0.02). Conclusion Urethral cancer is rare. Its incidence rates are highest in males, elderly patients, African Americans and in urothelial histological subtype. Most urethral cancer cases are T1N0M0, but over time, the incidence of T1N0M0 decreased in favor of T1-4N1-2M0.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence rates and contemporary trends in primary urethral cancer

Wenzel

Nocera

Ruvolo

et al. 2021

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Management of genitourinary malignancy is likely to demand a large portion of the urologist's time and practice, and the challenge for modern urology is not only in understanding the management of commonly seen genitourinary malignancies but also in identifying significant associations that can be risk factors in the development of malignant tumors. 1 Many biomarkers have been studied as assessors of outcomes in the development and treatment of malignant diseases, and one of them is the ABO blood group. Despite a multitude of studies attempting to correlate the ABO phenotype with cancer risk, the link between the expression of histoblood group antigens and tumorigenesis has remained unclear for most evaluated tumor types.…”

Section: Introductionmentioning

confidence: 99%

ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate

Milas,

Kaštelan,

Petrik

et al. 2024

Glob Med Genet

View full text Add to dashboard Cite

Background Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. Aim To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. Materials and Methods In the case–control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. Results No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 (p < 0.001), A1 (p < 0.001), and B (p = 0.013), and a lower proportion of metastatic disease in A2 (0%, p = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, p < 0.001), A1 (70.1%, p = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, p < 0.001), O2 (100%, p = 0.045), and recurrent tumors in patients with O1 (70.2%, p < 0.001) and A1 (74.2%, p = 0.007) alleles. Conclusion We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.

show abstract